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Abstract
CCL18, a chemokine with no known receptor, has been implicated in several fibrotic pulmonary diseases
associated with T-lymphocyte infiltration. It has been hypothesized that CCL18 may act through CCR6. Gene
delivery of human CCL18 to the lungs of wild-type mice induced pulmonary infiltration of T-lymphocytes, less than
5% of which expressed CCR6. In the lungs of CCR6-deficient mice, CCL18-driven infiltration of T-lymphocytes was
attenuated but not fully abrogated. It was concluded that CCR6 is not necessary for CCL18-induced changes in
mice in vivo and that CCR6 is not the main functional receptor for CCL18 in this model.
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Correspondence
CC chemokine ligand 18 (CCL18, also termed MIP-4,
PARC, AMAC-1, DC-CK-1 and SCYA18) is a chemo-
kine that has been implicated in several fibrotic pulmon-
ary diseases associated with T-lymphocyte infiltration
[1-5]. This cytokine has no known receptor and is pre-
sent in humans but not in mice [6-9], although human
CCL18 is fully functionally active in mice in vivo, caus-
ing chemotaxis of T-lymphocytes [3-5,9]. These observa-
tions suggest that although CCL18 was lost in mice after
evolutionary separation from human ancestors, the
receptor for it has been preserved in both mice and
humans. Identification of a functional CCL18 receptor
would allow for development of therapies targeting
CCL18-driven lymphocytic inflammation and fibrosis.
However, major efforts of numerous laboratories for
more than a decade failed to identify a CCL18 receptor.
At this point, excluding CCL18 receptor candidates
becomes important for narrowing the spectrum of
potential cell surface molecules that may band CCL18
and mediate its effects, and thus for avoiding duplicating
the efforts of various investigators.
It has been recently suggested [10] that CC chemokine
receptor 6 (CCR6) may be a functional receptor for
CCL18. CCR6 is known as the receptor for a different
chemokine, CCL20 (also termed LARC or MIP-3a), and
human CCL20 is biologically active in mice in vivo and
on mouse cells in culture [11,12]. Therefore, we
hypothesized that if CCR6 is a receptor for CCL18, the
effects of human CCL18 in mice [3-5,9] may be
mediated by mouse CCR6.
Findings
To address this hypothesis, two types of experiments
have been performed. In the first series of experiments,
wild-type C57Bl/6 mice (The Jackson Laboratory, Bar
Harbor, ME, USA) received intratracheal instillations of
a replication-deficient recombinant adenoviral construct
encoding human CCL18 (AdV-CCL18), exactly as
described previously [3-5]. Control mice received similar
amounts of AdV-NULL, which does not encode a cyto-
kine. Three animals per group were analyzed in two
independent experiments, with similar results. Fourteen
days after instillations, bronchoalveolar lavage (BAL)
was analyzed by flow cytometry, revealing a significant
accumulation of lymphocytes (22.1 ± 3.5% of total BAL
cells), in contrast to the number of lymphocytes found
in the BAL of AdV-NULL-treated mice (2.7 ± 0.8% of
total BAL cells). BAL cells were stained and analyzed
with flow cytometry for CD3 and CCR6. Only a small
fraction of T-lymphocytes stained positive for CCR6,
whereas nearly a quarter of the splenocytes obtained
from these mice were CCR6-positive (Figure 1A). These
observations suggested that human CCL18 attracts
* Correspondence: satamas@umaryland.edu
1Department of Medicine, University of Maryland School of Medicine,
Baltimore, MD 21201, USA
Full list of author information is available at the end of the article
Luzina and Atamas Fibrogenesis & Tissue Repair 2012, 5:2
http://www.fibrogenesis.com/content/5/1/2
© 2012 Luzina and Atamas; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.mostly CCR6-negative T-lymphocytes to mouse lungs,
and that mouse CCR6 is not necessary for the functional
response to human CCL18 in mice.
To further address this issue, we utilized homozygous
CCR6-deficient (CCR6-/-) mi c e( T h eJ a c k s o nL a b o r a -
tory). The CCR6-deficient status of these animals was
confirmed by flow cytometry (Figure 1A). Three
CCR6-/- and three wild-type mice were instilled with
AdV-CCL18 on two different occasions, and a histologic
analysis of the lung tissues was performed. In all cases,
gene delivery of human CCL18 caused lymphocytic infil-
tration of mouse lungs, as previously described [3-5],
although the infiltrates appeared smaller in the CCR6-/-
mice than in wild-type mice (Figure 1B). The smaller
size of the infiltrates in the CCR6-/- mice may be
explained by changes in the overall regulation of lym-
phocyte homeostasis in these animals [13]. Thus, lym-
phocytic infiltration of the lungs occurred in response to
CCL18 in CCR6-deficient animals.
Based on these combined observations, it was con-
cluded that mouse CCR6 is not necessary for CCL18-
induced changes in mice in vivo, and that CCR6 is not
the main functional receptor for CCL18 in this model.
These findings do not exclude the possibility that mice
and humans utilize different receptors for CCL18,
although this is unlikely considering the remarkable simi-
larity of CCL18 effects on human and mouse lympho-
cytes [3-5,9]. Further research is necessary to identify
CCL18 receptor(s), as the CCL18-dependent pathway is
centrally involved in a variety of maladies, particularly T-
lymphocyte-mediated fibrotic pulmonary diseases [1].
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